Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[HIV protease inhibitors: general review]

P Boudes1, J M Geiger

  • 1Centre International de Recherche Clinique Quintiles Strasbourg, Lingolsheim, France.

Therapie
|May 1, 1996
PubMed
Summary

Protease inhibitors offer a new treatment for HIV infection by blocking viral protein synthesis. While effective in reducing viral load and increasing CD4 counts, they can lead to resistant viral mutations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of acitretin in severe psoriasis.

Skin therapy letter·2003
Same author

[Endocrinolgy of estrogens: some recent developments and future applications].

Therapie·2000
Same author

Potential risk of birth defects after acitretin discontinuation.

Dermatology (Basel, Switzerland)·1999
Same author

Drug compliance in therapeutic trials: a review.

Controlled clinical trials·1998
Same author

A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.

Antiviral therapy·1996
Same author

Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings.

Journal of the American Academy of Dermatology·1996

Area of Science:

  • Virology
  • Pharmacology
  • Immunology

Context:

  • Human Immunodeficiency Virus (HIV) infection poses a significant global health challenge.
  • The HIV protease enzyme is essential for viral replication, cleaving polyproteins into functional units.
  • Developing targeted therapies is crucial for managing HIV disease.

Purpose:

  • To explore the role and efficacy of protease inhibitors as a novel therapeutic strategy for HIV.
  • To understand the mechanism of action of HIV protease inhibitors.
  • To evaluate the clinical outcomes and challenges associated with protease inhibitor therapy.

Summary:

  • Protease inhibitors are a new class of drugs demonstrating activity against HIV infection.
  • They target the HIV protease, inhibiting the cleavage of viral polyproteins, thereby preventing the formation of mature, infectious virions.
  • Clinical trials with saquinavir, indinavir, and ritonavir show reduced viral load (HIV-RNA PCR) and increased CD4 lymphocyte counts.

Impact:

  • Protease inhibitors represent a significant advancement in HIV treatment, offering a new therapeutic approach.
  • Their use, alone or in combination, has improved patient outcomes by controlling viral replication.
  • A key challenge is the rapid selection of drug-resistant HIV mutations, necessitating ongoing research and combination therapies.

Related Experiment Videos